Innovate Corp. 8-K Filing
Ticker: VATE · Form: 8-K · Filed: Dec 16, 2025 · CIK: 1006837
| Field | Detail |
|---|---|
| Company | Innovate Corp. (VATE) |
| Form Type | 8-K |
| Filed Date | Dec 16, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Innovate Corp. (ticker: VATE) to the SEC on Dec 16, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ich registered Common Stock, par value $0.001 per share VATE New York Stock Exchange).
How long is this filing?
Innovate Corp.'s 8-K filing is 2 pages with approximately 503 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 503 words · 2 min read · ~2 pages · Grade level 9.8 · Accepted 2025-12-16 08:07:05
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share VATE New York Stock Exchange
Filing Documents
- hchc-20251216.htm (8-K) — 34KB
- a202512168-kxexhibit991.htm (EX-99.1) — 22KB
- innovateforproxya.jpg (GRAPHIC) — 17KB
- 0001006837-25-000134.txt ( ) — 248KB
- hchc-20251216.xsd (EX-101.SCH) — 3KB
- hchc-20251216_def.xml (EX-101.DEF) — 17KB
- hchc-20251216_lab.xml (EX-101.LAB) — 30KB
- hchc-20251216_pre.xml (EX-101.PRE) — 17KB
- hchc-20251216_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On December 16, 2025, the Company issued a press release titled "MediBeacon Next Generation TGFR TM System Receives FDA Approval". A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act, except as shall be expressly set forth by specific reference in a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated December 16 , 2025, titled "MediBeacon Next Generation T GFR TM System Receives FDA Approval" 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 16, 2025 INNOVATE Corp. (Registrant) By: /s/ Michael J. Sena Name: Michael J. Sena Title: Chief Financial Officer